Compounding Pharmacy vs. Brand-Name Pathway: Two Very Different Prescription Routes

There are two fundamentally different prescription pathways for GLP-1 treatment — brand-name through a licensed retail pharmacy, or compounded through a telehealth-integrated compounding pharmacy. They're different processes, different regulatory status, different prices, and different risk profiles. Here's the complete comparison.

The brand-name pathway

Brand-name Wegovy, Zepbound, Ozempic, or Mounjaro is: FDA-approved for your indication, manufactured under FDA Good Manufacturing Practice standards, typically covered partially by insurance (when PA is approved), prescribed through any licensed provider including telehealth, and filled at a retail pharmacy (CVS, Walgreens, specialty mail-order). Pricing without insurance: $499–$1,500/month depending on drug and dose. With good insurance: $0–200/month copay.

The compounded pathway

Compounded semaglutide or tirzepatide is: produced by a 503A compounding pharmacy (individual prescription) or historically 503B outsourcing facility (bulk batch — under regulatory scrutiny as of 2026), not FDA-approved (the compounded version of the molecule, not the brand-name drug), typically cheaper ($150–350/month), prescribed through telehealth platforms, and shipped directly to you. Pricing advantage is significant; regulatory uncertainty has increased.

The 503A vs. 503B regulatory distinction

503A pharmacies fill individual patient prescriptions — these remain available under state pharmacy board oversight even after the shortage list removal. 503B outsourcing facilities, which produce large batches without individual prescriptions, are the target of FDA's proposed exclusion guidance. Most telehealth platforms that supply at scale use 503B supply chains — these face the higher regulatory risk.

Head-to-head comparison